(Q71697221)
Statements
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group (English)
Radlmaier A
Eickenberg HU
Fletcher MS
Fourcade RO
Reis Santos JM
van Aubel OG